Remimazolam

Byfavo (remimazolam) is a small molecule pharmaceutical. Remimazolam was first approved as Byfavo on 2020-10-06. It has been approved in Europe to treat conscious sedation. The pharmaceutical is active against gamma-aminobutyric acid receptor subunit beta-3, gamma-aminobutyric acid receptor subunit alpha-1, gamma-aminobutyric acid receptor subunit gamma-2, gamma-aminobutyric acid receptor subunit alpha-5, gamma-aminobutyric acid receptor subunit beta-2, gamma-aminobutyric acid receptor subunit alpha-2, gamma-aminobutyric acid receptor subunit alpha-6, gamma-aminobutyric acid receptor subunit alpha-3, gamma-aminobutyric acid receptor subunit alpha-4, gamma-aminobutyric acid receptor subunit beta-1, gamma-aminobutyric acid receptor subunit delta, gamma-aminobutyric acid receptor subunit epsilon, gamma-aminobutyric acid receptor subunit gamma-1, gamma-aminobutyric acid receptor subunit gamma-3, gamma-aminobutyric acid receptor subunit pi, and gamma-aminobutyric acid receptor subunit theta. Byfavo's patents are valid until 2033-04-30 (FDA).